Jan van Emous, Prilenia’s Vice President, Head of Regulatory Affairs, is responsible for leading the Company’s global regulatory strategy and all regulatory activities including the preparation for regulatory submissions in the US, Europe, and other regions. Jan has more than 20 years’ pharmaceutical industry experience, managing the regulatory review of new active substances and leading cross-functional teams. Jan joined Prilenia from Amylyx Pharmaceuticals, where he served as Head, Regulatory Affairs EMEA, responsible for the regional regulatory strategy for a potential new treatment for ALS in Europe and Japan. His expertise includes small molecules, biologicals (enzymes, MAbs, and gene therapy), rare diseases/orphan drug development and paediatric strategies. He has worked across several therapy areas, such as neurology, immunology, and rare genetic disorders and has previously held regulatory affairs roles for Organon/Schering Plough, Bristol Myers Squibb, Sanofi Genzyme and Novartis Gene Therapies (formerly AveXis). Jan is a medical biologist by training and earned his Ph.D. in experimental cardiology from UMC Utrecht. He is based in the Netherlands and in his spare time enjoys sailing the Dutch coastal waters as well as cycling and playing golf.

• 

  VP, Head of Regulatory Affairs in Prilenia

  Pursuing Hope. Leading With Science.